Logo

ZURA

Zura Bio Limited

ZURA

Zura Bio Limited • NASDAQ
$3.84 ▲ 1.05% (+0.04)
Market Cap $249.68 M
52w High $4.68
52w Low $0.97
Dividend Yield 0%
P/E -5.91
Volume 225.22K
Outstanding Shares 65.02M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $19.519M ▲ $-20.037M ▼ 0% $-0.21 ▼ $-18.026M ▲
Q2-2025 $0 $18.062M ▼ $-15.993M ▲ 0% $-0.17 ▲ $-18.051M ▲
Q1-2025 $0 $19.254M ▲ $-17.442M ▼ 0% $-0.19 ▼ $-19.245M ▼
Q4-2024 $0 $15.727M ▼ $-9.048M ▲ 0% $-0.14 ▲ $-13.62M ▲
Q3-2024 $0 $19.319M $-20.702M 0% $-0.26 $-19.316M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $139.017M ▼ $143.935M ▼ $25.491M ▲ $108.243M ▼
Q2-2025 $154.49M ▼ $157.805M ▼ $18.696M ▼ $125.905M ▼
Q1-2025 $170.569M ▼ $172.496M ▼ $21.092M ▲ $138.2M ▼
Q4-2024 $176.498M ▼ $179.533M ▼ $19.514M ▲ $146.815M ▼
Q3-2024 $188.221M $189.071M $18.244M $153.046M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-20.037M ▼ $-15.444M ▲ $-32K ▼ $3K ▲ $-15.473M ▲ $-15.476M ▲
Q2-2025 $-15.993M ▲ $-16.03M ▼ $-15K ▲ $-34K ▼ $-16.079M ▼ $-16.045M ▼
Q1-2025 $-17.442M ▼ $-11.063M ▼ $-49K ▼ $5.183M ▲ $-5.929M ▲ $-11.112M ▼
Q4-2024 $-11.288M ▲ $-10.824M ▼ $-45K ▼ $-854K ▼ $-11.723M ▼ $-10.869M ▼
Q3-2024 $-20.702M $-5.653M $-13K $5.444M $-222K $-5.666M

Five-Year Company Overview

Income Statement

Income Statement Zura Bio is a classic early-stage biotech story: no product revenue yet and ongoing losses driven by research and operating costs. The good news is that losses appear relatively contained and not exploding over time, which suggests some cost discipline. However, the company is still firmly in the “investment phase,” where success depends entirely on turning today’s R&D spending into future approved drugs. Until there is either partnership income or product sales, the income statement will likely stay in the red and remain sensitive to trial pace and staffing decisions.

Balance Sheet

Balance Sheet The balance sheet is lean but relatively clean. Assets are largely made up of cash, with no meaningful debt, which reduces financial strain and interest obligations. Shareholders’ equity has moved from negative to positive territory, reflecting fresh capital and a healthier financial footing after the SPAC process. Still, the company is small, with limited hard assets, so its strength rests mainly on its cash position and the perceived value of its drug pipeline rather than on tangible resources.

Cash Flow

Cash Flow Cash flow reflects what you would expect from a clinical-stage biotech: money flowing out to fund trials, salaries, and supporting infrastructure, with no offsetting inflows from product sales. Operating cash burn appears steady rather than sharply rising, and capital spending needs are modest, which helps extend the runway. Even so, the business is not self-funding; over time it will likely need either new capital, partnerships, or milestone payments to sustain development, particularly if timelines slip or the pipeline expands.

Competitive Edge

Competitive Edge Zura Bio is trying to stand out in a crowded immunology field by focusing on dual-pathway antibody therapies for difficult autoimmune and inflammatory diseases. The lead asset, which hits both IL‑17A and BAFF, is aimed at conditions with few effective options, like systemic sclerosis and hidradenitis suppurativa. This focus on high unmet need can be a strategic advantage if the drugs show clear benefits. At the same time, Zura is competing with very large pharmaceutical companies working on overlapping pathways, so it will need convincingly better data, a clear safety profile, and smart trial design to earn a durable place in the market.

Innovation and R&D

Innovation and R&D Innovation is the core of Zura Bio’s value. Its lead bispecific antibody is a genuinely differentiated approach, trying to control both inflammation and fibrotic processes at once, which could matter a lot in complex diseases. Alongside this, Zura has two more clinical-stage antibodies aimed at well-known immune pathways (IL‑7/TSLP and IL‑33), where competition is intense but scientific validation is strong. The pipeline is focused rather than broad, so success or failure of a few key trials—particularly the planned Phase 2 readouts in the second half of this decade—will heavily shape the company’s future. The long gap until those data arrive is both an opportunity for careful development and a risk, given the speed at which competitors can move.

Summary

Overall, Zura Bio is an early-stage, science-driven biotech with no revenues yet, a relatively clean, cash-based balance sheet, and a controlled but persistent cash burn. Its potential value rests on an innovative dual-pathway strategy and a small set of clinical assets aimed at diseases with significant unmet needs. The main strengths are its differentiated lead program, focus on high-need conditions, and lack of debt. The main risks are typical for its stage: complete dependence on future trial results, heavy competition from much larger players, regulatory and scientific uncertainty, and the likelihood of needing future funding or partnerships. The story is highly binary and will be shaped by clinical readouts and capital-raising or deal-making over the next few years.

NEWS

November 13, 2025 · 6:30 AM UTC

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

Read more